Active-comparator design and new-user design in observational studies

Nature Reviews Rheumatology

Volumn 11, Issue 7, 2015, Pages 437-441

  Yoshida, Kazuki ^a   Solomon, Daniel H ^a   Kim, Seoyoung C ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR INHIBITOR;

COHORT ANALYSIS; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INFECTION; NEOPLASM; OBSERVATIONAL STUDY; PATIENT ASSESSMENT; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; TREATMENT INDICATION; ARTHRITIS, RHEUMATOID; EPIDEMIOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICAL BIAS;

ARTHRITIS, RHEUMATOID; BIAS (EPIDEMIOLOGY); CONFOUNDING FACTORS (EPIDEMIOLOGY); HUMANS; OBSERVATIONAL STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84933676446     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2015.30     Document Type: Review

References (26)

1. Chan, K. A. & Hernandez-Diaz, S. Pharmacoepidemiology and rheumatic disorders. Rheum. Dis. Clin. North Am. 30, 835-850 (2004
2. Schneeweiss, S., Gagne, J. J., Glynn, R. J., Ruhl, M. & Rassen, J. A. Assessing the comparative effectiveness of newly marketed medications: methodological challenges and implications for drug development. Clin. Pharmacol. Ther. 90, 777-790 (2011
3. Strom, B. L., Kimmel, S. E. & Hennessy, S. (Eds) Textbook of Pharmacoepidemiology (Wiley-Blackwell, 2013
4. Walker, A. M. & Stampfer, M. J. Observational studies of drug safety. Lancet 348, 489 (1996
5. Psaty, B. M. & Siscovick, D. S. Minimizing bias due to confounding by indication in comparative effectiveness research: the importance of restriction. JAMA 304, 897-898 (2010
6. Rosenbaum, P. R. & Rubin, D. B. The central role of the propensity score in observational studies for causal effects. Biometrika 70, 41-55 (1983
7. Crump, R. K., Hotz, V. J., Imbens, G. W. & Mitnik, O. A. Dealing with limited overlap in estimation of average treatment effects. Biometrika 96, 187-199 (2009
8. Petersen, M. L., Porter, K. E., Gruber, S., Wang, Y. & van der Laan, M. J. Diagnosing and responding to violations in the positivity assumption. Stat. Methods Med. Res. 21, 31-54 (2012
9. Dixon, W. G., et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann. Rheum. Dis. 69, 522-528 (2010
10. Sternberg, S. A., Wershof Schwartz, A., Karunananthan, S., Bergman, H. & Clarfield, A. M. The identification of frailty: a systematic literature review. J. Am. Geriatr. Soc. 59, 2129-2138 (2011
11. Glynn, R. J., Knight, E. L., Levin, R. & Avorn, J. Paradoxical relations of drug treatment with mortality in older persons. Epidemiology 12, 682-689 (2001
12. Eurich, D. T., Marrie, T. J., Johnstone, J. & Majumdar, S. R. Mortality reduction with influenza vaccine in patients with pneumonia outside 'flu' season: pleiotropic benefits or residual confounding? Am. J. Respir. Crit. Care Med. 178, 527-533 (2008
13. Camelo Castillo, W., Delaney, J. A. C. & Stürmer, T. The challenges of comparing results between placebo controlled randomized trials and non-experimental new user, active comparator cohort studies: the example of olmesartan. Pharmacoepidemiol. Drug Saf. 23, 357-360 (2014
14. Ray, W. A. Evaluating medication effects outside of clinical trials: new-user designs. Am. J. Epidemiol. 158, 915-920 (2003
15. Johnson, E. S., et al. The incident user design in comparative effectiveness research. Pharmacoepidemiol. Drug Saf. 22, 1-6 (2013
16. Strangfeld, A., et al. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann. Rheum. Dis. 70, 1914-1920 (2011
17. Choi, H. K., Nguyen, U. S., Niu, J., Danaei, G. & Zhang, Y. Selection bias in rheumatic disease research. Nat. Rev. Rheumatol. 10, 403-412 (2014
18. Curtis, J. R., et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor α antagonists. Arthritis Rheum. 56, 1125-1133 (2007
19. Dixon, W. G., et al. Serious infection following anti-Tumor necrosis factor α therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum. 56, 2896-2904 (2007
20. Askling, J., et al. Cancer risk in patients with rheumatoid arthritis treated with anti-Tumor necrosis factor α therapies: does the risk change with the time since start of treatment? Arthritis Rheum. 60, 3180-3189 (2009
21. Schisterman, E. F., Cole, S. R. & Platt, R. W. Overadjustment bias and unnecessary adjustment in epidemiologic studies. Epidemiology 20, 488-495 (2009
22. Suissa, S. Immortal time bias in observational studies of drug effects. Pharmacoepidemiol. Drug Saf. 16, 241-249 (2007
23. Levesque, L. E., Hanley, J. A., Kezouh, A. & Suissa, S. Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ 340, b5087 (2010
24. Rothman, K. J., Greenland, S. & Lash, T. L. Modern Epidemiology (Lippincott Williams & Wilkins, 2012
25. Grijalva, C. G., et al. Initiation of tumor necrosis factor α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA 306, 2331-2339 (2011
26. Strangfeld, A., et al. Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res. Ther. 12, R5 (2010